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Abstract A pilot expanded newborn screening programme
to detect inherited metabolic disorders by means of liquid
chromatography coupled with tandem mass spectrometry
(LC-MS/MS) began in the Campania region, southern Italy,
in 2007. By October 2009, >8,800 dried blood samples on
filter paper from 11 hospitals had been screened. Within this
screening programme, we identified a case of mitochondrial
acetoacetyl-coenzyme A (CoA) thiolase deficiency [β-keto-
thiolase (β-KT) deficiency] by analysing the acylcarnitine
profile from a dried blood spot with LC-MS/MS. Gas
chromatography coupled with mass spectrometry analysis of
urinary organic acids and LC-MS/MS analysis of urinary
acylcarnitines were in line with this disorder. In fact, concen-
trations were well beyond the cut-off values of tiglyl carnitine,
3-hydroxybutyrylcarnitine and 2-methyl-3-hydroxybutyrylcar-
nitine, 2-methyl-3-hydroxybutyric acid and tiglyl glycine. The
absence of 2-methylacetoacetic acid in urine may be
attributed to: (i) the instability of this β-ketoacid because
it undergoes spontaneous decarboxylation to 2-butanone,
which is highly volatile and thus difficult to detect, and (ii)
the good health of the patient in the first days of life. β-KT
deficiency was subsequently diagnosed in the patient's
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older sister, who showed increased levels of the same
metabolites but also small amounts of 2-methylacetoacetic
acid, which is considered a key marker for β-KT
diagnosis. Genomic analysis revealed mutation c.1189C
>G in exon 12 of the ACAT1 gene, which results in a
severe defect because of the p.H397D amino acid change
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A pilot expanded newborn screening programme to detect
inherited metabolic disorders by means of liquid chromatog-
raphy coupled with tandem mass spectrometry (LC-MS/MS)
began in the Campania region, southern Italy, in 2007. By
October 2009, >8,800 dried blood samples on filter paper
from 11 hospitals in the region had been screened in our
laboratory.Within this programme, we detectedmitochondrial
acetoacetyl-coenzyme A (CoA) thiolase deficiency (β-KT
deficiency) in a newborn asymptomatic girl and in her older
sister who had a metabolic decompensation event a few
months earlier (Fig. 1). In the proband, β-KT deficiency was
diagnosed by analysing the patient’s acylcarnitine profile on
a dried blood spot and in urine by using liquid chromatog-
raphy coupled with tandem mass spectrometry (LC-MS/MS)
and gas chromatography coupled with mass spectrometry
(GC/MS) using previously described procedures (Chace




















Fig. 1 Dual function of
acetoacetyl-coenzyme A (CoA)
thiolase [ACAT 1 (β-KT)] in
isoleucine and ketone body me-
tabolism. Metabolite biomarkers
of β-KT deficiency are boxed
J Inherit Metab Dis (2010) 33    (Suppl 3):S91–S94S92
Results
Patient 1
The proband, a girl, was born after 41 weeks of an
uncomplicated pregnancy, the second child of healthy
parents who were third cousins. Birth weight was 3,390 g
(50th centile), length 53 cm (50th–75th centile) and head
circumference 36 cm (50th–75th centile). No clinical
abnormalities were found in the first days of life. The
Apgar score was 9 at 1 min and 10 at 5 min. The mother
was 25 years old and the father 27. The amino acid profile
determined in a dried blood spot when patient 1 was 4 days
old was normal, whereas acylcarnitine analysis revealed
increased concentrations of tiglylcarnitine (C5:1=
0.34 μmol/L; upper cut-off = 0.23 μmol/L), 3-
hydroxybutyrylcarnitine (C4OH=2.19 μmol/L; upper cut-
off = 0.55 μmol/L) and 2-methyl-3-hydroxybutyrylcarnitine
(C5OH=1.17 μmol/L; upper cut-off = 0.28 μmol/L).
Analysis of acylcarnitines in urine samples confirmed
elevated concentrations of C5:1 (2.68 mmol/mol creatinine;
upper cut-off = 0.20 mmol/mol creatinine) and C5OH
(1.08 mmol/mol creatinine; upper cut-off = 0.54 mmol/mol
creatinine). C5:1 and C5OH concentrations are elevated in
both β-KT deficiency and 2-methyl-3-hydroxybutyryl-CoA
dehydrogenase deficiency (MHBD deficiency) (Matern et
al 2003), whereas increased concentrations of C4OH have
been identified only in cases of β-KT deficiency (Han et al
2007 and http://region4genetics.org). Therefore, elevated
C4OH concentrations were highly suggestive of β-KT
deficiency in patient 1. To verify the diagnosis, we analysed
urine organic acids. Results showed that patient 1 had
abnormal excretion of 2-methyl-3-hydroxybutyric acid
(441 mmol/mol creatinine; upper cut-off = 2 mmol/mol
creatinine) and tiglylglycine (87 mmol/mol creatinine;
upper cut-off = 2 mmol/mol creatinine). Detection of 2-
methylacetoacetic acid in the urine organic acid profile is
considered a key factor for a diagnosis of β-KT deficiency; 2-
methylacetoacetic acid is unstable because it undergoes
spontaneous decarboxylation to 2-butanone, which is highly
volatile and is therefore not easily determined (Korman
2006). Its absence in the urine of patient 1 can probably be
attributed to her good health because of the earlier diagnosis
consequent to neonatal screening.
Patient 2
Birth weight of the older sister of patient 1 was 3,240 g
(25th centile). She was born after an uncomplicated
pregnancy. At 18 months of age, after gastroenteritis and
a vomiting event, she entered an emergency unit because of
lethargy and metabolic acidosis (pH 7.07, HCO3
- 5.2). The
metabolic decompensation was treated with bicarbonate
infusion. β-KT deficiency was diagnosed when the patient
was 23 months old and in an asymptomatic condition soon
after the metabolic defect was discovered in her sister.
Serum and urine acylcarnitine analysis in patient 2 revealed
elevated concentrations of both C5:1 (serum: 0.96 μmol/L
with an upper cut-off = 0.12 μmol/L; urine: 12.8 mmol/mol
creatinine with an upper cut-off = 0.2 mmol/mol creatinine)
and C5OH (serum: 0.70 μmol/L with an upper cut-off =
0.13 μmol/L; urine: 2.06 mmol/mol creatinine with an
upper cut-off = 0.54 mmol/mol creatinine). Urine organic
acid analysis revealed massive excretion of 2-methyl-3-
hydroxybutyric acid (1,354 mmol/mol creatinine; upper
cut-off = 2 mmol/mol creatinine) and tiglylglycine
(825 mmol/mol creatinine; upper cut-off = 2 mmol/mol
creatinine) and small amounts of 2-methylacetoacetic acid
(25 mmol/mol creatinine). Thus, taken together, the data
suggested β-KT deficiency in this patient and indirectly
confirmed the same diagnosis in the younger sister.
Familial genomic analysis
To reach a more robust diagnosis, we carried out a genomic
analysis in both sisters and their parents. We sequenced the
amplified fragments corresponding to exons 1–12 of the
ACAT1 gene and identified the c.471C >A p.S547S
(rs35188041) polymorphism in exon 6 and the c.1189C >G
p.H397D mutation in exon 12, both at the homozygous state
in the two patients. The parents were found to be heterozy-
gous for both the polymorphism and the mutation, thus
confirming the homozygosity of the two daughters. The
H397Dmutation changes an amino acid residue that is highly
conserved among species. The H397D mutation provokes a
null allele in the sense that it causes the total loss of
acetoacetyl-CoA thiolase activity for which the potassium
ion is critical (Fukao et al 2003, 2008; Haapalainen et al
2007). Such a severe three-dimensional perturbation desta-
bilises the overall integrity of the mutant enzyme (Zhang et
al 2004).
Discussion
Here we report the clinical and biological investigations
carried out in two sisters in whom we identified β-KT
deficiency. Using LC-MS/MS within a pilot extended
metabolic screening programme, we diagnosed β-KT
deficiency by analysing the blood spot of patient 1.
Subsequently, we identified the same metabolic defect in
the patient’s sister by analysing a serum sample. In the next
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level of diagnosis, we examined urinary organic acids using
GC/MS in both sisters. This analysis revealed abnormal
excretion of 2-methyl-3-hydroxybutyric acid and tiglylgly-
cine in both patients and a small amount of 2-
methylacetoacetic acid in the older sister. Familial genomic
analysis confirmed that both sisters are affected by β-KT
deficiency and showed that they are homozygotes for the
c.1189C >G (p.H397D) mutation in exon 12 of the ACAT1
gene; the parents are heterozygotes for the same mutation.
The mutation has been classified as a severe defect because
it abolishes protein expression, as demonstrated in an in
vitro assay (Zhang et al 2004).
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